Spirepoint Private Client’s Gilead Sciences GILD Stock Holding History

Spirepoint Private Client’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.3M	Buy	81,278 +879	+1%	+$116K	0.83%	33
2026 Q1	$11.2M	Buy	80,399 +4,053	+5%	+$568K	1.07%	27
2025 Q4	$9.37M	Buy	76,346 +10,780	+16%	+$1.31M	0.9%	32
2025 Q3	$7.28M	Buy	65,566 +2,710	+4%	+$308K	0.77%	45
2025 Q2	$6.97M	Buy	62,856 +1,041	+2%	+$111K	0.79%	39
2025 Q1	$6.93M	Buy	+61,815	New	+$6.38M	0.9%	37

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Spirepoint Private Client's GILD Position: Q2 2026 in Review

Spirepoint Private Client increased its Gilead Sciences (GILD) stake by 1.1% in Q2 2026, buying an estimated $116K and bringing the position to 81,278 shares worth $10.3M. The position accounts for 0.83% of the portfolio, ranked #33.

Spirepoint Private Client first reported a position in GILD in Q1 2025 and has held it in 6 quarters since. The position peaked at $11.2M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Spirepoint Private Client held 81,278 shares of Gilead Sciences worth $10.3M as of Q2 2026.
Spirepoint Private Client bought 879 Gilead Sciences shares in Q2 2026, an estimated $116K.
Gilead Sciences made up 0.83% of Spirepoint Private Client's portfolio in Q2 2026, its #33 holding.
Spirepoint Private Client first reported a position in Gilead Sciences in Q1 2025 and has held it in 6 quarters since.
Spirepoint Private Client's Gilead Sciences position peaked at $11.2M in Q1 2026.
2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Spirepoint Private Client's 13F filing for Q2 2026, filed 5 Aug 2026.